Fluxion Biosciences Receives $1.2M NIH Grant for Development of Drug Discovery Platform
Grant Funds Development of Multiplexed Single-Cell Electroporation System
for Highly Controlled siRNA Delivery
(Link to Yahoo Finance Version)
Thursday May 17, 2007 , 4:00 pm ET
SAN FRANCISCO--(BUSINESS WIRE)-- Fluxion Biosciences, a leading developer of microfluidic systems for cellular analysis in life sciences research and drug discovery, today announced that it has received a $1.2 million NIH grant for the development of a multiplexed single-cell electroporation system. The Phase II SBIR grant continues the successful development that was funded by NIH as part of a Phase I project completed in 2006.
The newly awarded grant will further the development of Fluxion's intracellular delivery platform. Fluxion is developing a benchtop workstation capable of selecting, trapping, and delivering biological reagents inside individual cells in a highly controlled manner. Applications for this system include siRNA delivery, protein pathway mapping, and stem cell research. The specific goal of this research grant is the development of a high throughput prototype capable of combining electroporation for intracellular delivery with integrated functional cell analysis.
"We are excited to receive this NIH grant for the continued development of our single-cell electroporation technology," said Cristian Ionescu-Zanetti, Ph.D., co-founder and Chief Technology Officer. "The ability to carefully control delivery of siRNA, proteins, and other reagents to individual cells offers significant potential to aid research in a number of critical areas, including systems biology research and drug discovery."
About Fluxion Biosciences
Fluxion Biosciences develops cellular analysis tools for use in critical applications in life sciences research and drug discovery. Fluxion’s proprietary microfluidic platform, CellFlux, enables precise functional analysis of individual cells in a highly multiplexed format. Products include the BioFlux System for biofilm and cellular adhesion assays, IonFlux System for cellular electrophysiology, and the CytoFlux System for stop-flow imaging cytometry. These products meet the rigorous demands of life science and drug discovery scientists by providing an intuitive, easy-to-use "operating system" for single-cell biology. For more information about Fluxion Biosciences, visit www.fluxionbio.com.
Contact:
Jeff Jensen, CEO
Fluxion Biosciences
1700 4th St.
San Francisco, CA 94158
925-518-7046
jeff.jensen@fluxionbio.com
Home About Products Technology News Contact
© 2007 Fluxion Biosciences, Inc. All rights reserved.
"BioFlux", "CytoFlux" and "IonFlux" are trademarks of Fluxion Biosciences, Inc.